We have conducted a pilot investigation to examine the potential of the MBT to (1) assess malabsorption in subjects with CF and PI compared to healthy volunteer controls and (2) judge the effectiveness of pancreatic lipase inhibition as proof of mechanism for the combined administration of PA and HA to discriminate pancreatic enzyme-based fat malabsorption. The gene discussed is PNLIP; the disease is cystic fibrosis.